^
Association details:
| Biomarker: | FGF19 overexpression |
|---|---|
| Cancer: | Hepatocellular Cancer |
| Drug: | fisogatinib (BLU-554) (FGFR4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma
Excerpt:
Fisogatinib elicited clinical responses in patients with tumor FGF19 overexpression in advanced HCC.
DOI:
10.1158/2159-8290.CD-19-0555
